Edwards Lifesciences
740 hedge funds and large institutions have $19.3B invested in Edwards Lifesciences in 2017 Q3 according to their latest regulatory filings, with 82 funds opening new positions, 270 increasing their positions, 258 reducing their positions, and 55 closing their positions.
49% more first-time investments, than exits
New positions opened: 82 | Existing positions closed: 55
3% more funds holding
Funds holding: 721 → 740 (+19)
5% more repeat investments, than reductions
Existing positions increased: 270 | Existing positions reduced: 258
0.92% less ownership
Funds ownership: 251.87% → 250.95% (-0.92%)
7% less capital invested
Capital invested by funds: $20.8B → $19.3B (-$1.52B)
28% less call options, than puts
Call options by funds: $80.2M | Put options by funds: $112M
29% less funds holding in top 10
Funds holding in top 10: 14 → 10 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$154M |
| 2 |
BlackRock
New York
|
+$111M |
| 3 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
+$92.1M |
| 4 |
NSLI
Nan Shan Life Insurance
Taipei City,
Taiwan
|
+$69.8M |
| 5 |
Janus Henderson Group
London,
|
+$65.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Brown Advisory
Baltimore,
Maryland
|
-$112M |
| 2 |
HM
HealthCor Management
New York
|
-$98.6M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$83.1M |
| 4 |
FAM
Fred Alger Management
New York
|
-$68.7M |
| 5 |
Winslow Capital Management
Minneapolis,
Minnesota
|
-$68.4M |
EW Hedge Fund Activity: Q3 2017 in Review
740 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q3 2017, worth a combined $19.3B — down 7.3% from $20.8B a quarter earlier.
Buyers outnumbered sellers: 82 funds opened new EW positions and 55 closed out — a net gain of 27 holders — while 270 added to existing stakes and 258 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $154M. The largest seller was Brown Advisory, cutting an estimated $112M.
- 740 institutional investors held Edwards Lifesciences (EW) as of Q3 2017, up from 721 in Q2 2017.
- Funds reported $19.3B of Edwards Lifesciences stock for Q3 2017, down 7.3% quarter-over-quarter.
- 82 funds opened new Edwards Lifesciences positions in Q3 2017 and 55 closed out, a net change of +27 holders.
- The largest Edwards Lifesciences buyer in Q3 2017 was Renaissance Technologies, an estimated $154M added.
- The largest Edwards Lifesciences seller in Q3 2017 was Brown Advisory, an estimated $112M sold.
Based on aggregated 13F filings for Q3 2017.